Newron Pharmaceuticals (NWPHF) Stock Price, News & Analysis

Company Overview

Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.

Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease. Licensed to Zambon for commercialization in Europe and to a partner for the U.S. market, safinamide has received approval from regulatory authorities including the European Medicines Agency and the U.S. Food and Drug Administration. The company’s pipeline also includes evenamide, a selective sodium channel modulator in clinical development for schizophrenia, alongside earlier-stage programs targeting neuropathic pain.

Newron maintains strategic collaborations with global pharmaceutical firms to advance its late-stage assets through regulatory approval and into commercialization. This licensing model allows the company to leverage the market reach and infrastructure of established partners while retaining rights in select territories. Research partnerships with academic institutions in Europe further support its discovery efforts.

Founded in 2003 by a team of neuroscientists, Newron has evolved from early research initiatives into a publicly traded entity on the OTC Markets under the symbol NWPHF. With a management team experienced in drug development and commercialization, the company continues to expand its CNS-focused portfolio, exploring opportunities for growth in existing and new therapeutic areas.

Key Stats

• Today's Range: $20.00 to $20.00
• 50-Day Range: $9.36 to $20.00
• 52-Week Range: $9.10 to $20.00
• Volume: N/A
• Average Volume: 600 shs
• Market Capitalization: $357 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 5/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NWPHF
• CIK: N/A
• Web: www.newron.com
• Phone: (902) 610-3461
• Fax: 39-02-6103-4654
• Employees: 22
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $6.82 million
• Price / Sales: 52.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.21 per share
• Price / Book: 95.24

Miscellaneous

• Outstanding Shares: 17,850,000
• Free Float: N/A
• Market Cap: $357 million
• Optionable: Not Optionable
• Beta: 0.53